Drug Information

Drug (ID: DG01685) and It's Reported Resistant Information

• Name: Everolimus/Binimetinib
• Synonyms: Everolimus/Binimetinib
• Target: .; NOUNIPROTAC; [1]

Type(s) of Resistant Mechanism of This Drug

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Brain cancer [ICD-11: 2A00]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: GTPase Nras (NRAS) [1]

• Molecule Alteration: Missense mutation; p.Q61K (c.181C>A)
• Sensitive Disease: Neuroblastoma [ICD-11: 2A00.11]
• Experimental Note: Identified from the Human Clinical Data
• Cell Pathway Regulation: PI3K/mTOR signaling pathway; Inhibition; hsa04151
• In Vitro Model: Sk-N-AS cells; Adrenal; Homo sapiens (Human); CVCL_1700
• In Vitro Model: SH-SY5Y cells; Abdomen; Homo sapiens (Human); CVCL_0019
• In Vitro Model: NGP cells; Lung; Homo sapiens (Human); CVCL_2141
• In Vitro Model: CHP-212 cells; Brain; Homo sapiens (Human); CVCL_1125
• In Vitro Model: CHP-134 cells; Adrenal gland; Homo sapiens (Human); CVCL_1124
• Experiment for Molecule Alteration: Western blotting analysis; PCR
• Experiment for Drug Resistance: Promega assay; FACS assay
• Mechanism Description: Combination of mTOR and MEK inhibitors synergistically inhibit downstream signaling and cell growth of NRAS mutant cell lines.

References

• Ref 1: Targeting the mTOR Complex by Everolimus in NRAS Mutant NeuroblastomaPLoS One. 2016 Jan 28;11(1):e0147682. doi: 10.1371/journal.pone.0147682. eCollection 2016.